MSB 1.02% 97.0¢ mesoblast limited

http://seekingalpha.com/news/272033...ical-trials-in-japan?uprof=...

  1. 220 Posts.
    http://seekingalpha.com/news/272033...ical-trials-in-japan?uprof=45&dr=1#email_link

    Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approvesPluristem Therapeutics' (NASDAQSTI) PLX-PAD cells for use in clinical trials in country. The clearance will enable the company to commence a Phase 2 study ofPLX-PAD in critical limb ischemia through Japan's accelerated regulatory pathway for regenerative medicine which allows for conditional, time-limited marketing approval after a single successful Phase 2 trial.The company intends to talk with the PDMA in Q4 to finalize the protocol. It expects to receive permission in Q4 to start the trial, which should commence in Q1 2016.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.0¢
Change
-0.010(1.02%)
Mkt cap ! $1.107B
Open High Low Value Volume
98.0¢ 98.5¢ 95.5¢ $6.248M 6.438M

Buyers (Bids)

No. Vol. Price($)
1 10000 96.5¢
 

Sellers (Offers)

Price($) Vol. No.
97.0¢ 116040 7
View Market Depth
Last trade - 16.10pm 26/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.